Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (15125)	2/15/1998 6:36:00 AM
From: Henry Niman	Respond to of 32384

Torben , I agree that the understanding of why the breast tumors were so responsive to Targretin, will pay dividends big time down the road. As more and more products come to market, the physician and health care system will become increasingly overwhelmed with treatment options. It will become important to identify which combinations will work with which patients, and to identify the appropriate subpopulations before treatment begins. Thus, if Targretin works well on breast cancer patients (and other cancer patients) with a mutated ras oncogene, then the patients will be screened and those with the marker will be treated with Targretin (and Tamoxifen?). Alternatively, the marker for successful treatment could be elevated levels of IGFII, or some other marker (or more likely, a combination of markers). More information at the molecular level will lead to better diagnosis, treatment, and monitoring, and LGND is well positioned to develop all of these areas.